Aerosol research instrument company Inhalation Sciences (ISAB) has announced the formation of a new scientific advisory board, which will begin meeting on June 1, 2021 to discuss how the company's PreciseInhale laboratory aerosol dosing system can be used once it has been validated for clinical use. Members of the new scientific advisory board include Carsten Ehrhardt … [Read more...] about Inhalation Sciences forms new scientific advisory board
News
GSK sells its stake in Innoviva
Innoviva is buying back GlaxoSmithKline's entire stake in the company, a total of 32 million shares (~ 32% of company). Innoviva (formerly Theravance, Inc.), was spun off from Theravance in 2013 to manage the royalties from dry powder inhalers that Theravance developed in partnership with GSK, including Relvar/Breo Ellipta, Anoro Ellipta, and Trelegy Ellipta. GSK will … [Read more...] about GSK sells its stake in Innoviva
Kindeva partners with Loughborough on low-GWP MDI propellants
Kindeva Drug Delivery (formerly 3M Drug Delivery Systems) has signed a knowledge transfer partnership (KTP) with Loughborough University for the development of lower GWP MDI propellants, the company announced. Kindeva says that it "will leverage the KTP to understand the physics involved in pharmaceutical spray generation, using computational fluid dynamic (CFD) … [Read more...] about Kindeva partners with Loughborough on low-GWP MDI propellants
Iconovo announces deal with Respiratorius for development of DPI
Iconovo will develop a dry powder formulation and a DPI for Phase 1 studies for Swedish respiratory drug company Respiratorius AB on a fee for service basis in a deal worth up to SEK 3 million, the company said. The project, which involves development of Respiratorius's RES030-085 for the treatment of COPD and severe asthma, would lead to a license agreement if … [Read more...] about Iconovo announces deal with Respiratorius for development of DPI
Aerovate names Timothy Noyes as CEO
Aerovate Therapeutics has announced that former Proteon Therapeutics President and CEO Timothy Noyes has been named CEO and elected to the company's board of directors. Noyes was most recently CEO of Arcuate Therapeutics, and he previously served in executive roles at Genzyme and GelTex Pharmaceuticals after beginning his career at Merck. Aerovate's lead candidate is … [Read more...] about Aerovate names Timothy Noyes as CEO
Ji Xing Pharmaceuticals gets Chinese rights to etripamil for PVST
Milestone Pharmaceuticals has announced a new agreement with Ji Xing Pharmaceuticals giving Ji Xing Chinese development and commercialization rights to Milestone's etripamil nasal spray in patients with cardiovascular conditions, including paroxysmal supraventricular tachycardia (PSVT). Ji Xing will pay $15 million up front and up to $107.5 million in milestone and … [Read more...] about Ji Xing Pharmaceuticals gets Chinese rights to etripamil for PVST
Koura launches HFA-152a development services
MDI propellant maker Koura has announced the launch of HFA-152a development and filling services at the company's facilities in Chester, UK. Koura (formerly Mexichem) first announced the possibility of using 152a as a low global warming potential (GWP) propellant for metered dose inhalers in 2016. In December 2019, Chiesi announced that it planned to bring a … [Read more...] about Koura launches HFA-152a development services
Seelos announces positive Phase 2 results for SLS-002 intranasal racemic ketamine for suicidal ideation
Seelos Therapeutics said that the first part of a Phase 2 study of its SLS-002 intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder (MDD) demonstrated significant reductions in suicidality and depression. Seelos had announced the initiation of the study in January 2021. The open label portion … [Read more...] about Seelos announces positive Phase 2 results for SLS-002 intranasal racemic ketamine for suicidal ideation
Akroswiss gets funding for development of midazolam nasal spray
Swiss start-up Akroswiss has announced that it raised "several million Swiss Franc" for development of the company's midazolam nasal spray for the prevention of claustrophobia and for the rescue treatment of epileptic seizures. Investors include Linsi, Bernhard Schuknecht, and Walter P. Hölzle, who is also the company's Head of Business Development. According to the … [Read more...] about Akroswiss gets funding for development of midazolam nasal spray
Iconovo announces expansion of deal with Amneal on generic Symbicort and launch of pharma division
DPI developer Iconovo has announced that its development deal with Amneal for a generic version of Symbicort has been amended to add US and Chinese marketing rights for Amneal and Nordic region marketing rights for Iconovo. Acquisition of the Nordic marketing rights also marks the launch of a new division of Iconovo, Iconovo Pharma. The original deal included … [Read more...] about Iconovo announces expansion of deal with Amneal on generic Symbicort and launch of pharma division